5α-Oestran-17-on | 25824-86-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 5α-Oestran-17-on
• 英文别名: (5R,8R,9R,10S,13S,14S)-13-methyl-2,3,4,5,6,7,8,9,10,11,12,14,15,16-tetradecahydro-1H-cyclopenta[a]phenanthren-17-one
• CAS: 25824-86-6
• 化学式: C₁₈H₂₈O
• 分子量: 260.42
• InChiKey: WYRCRDCGMYGWKP-IDUQQSTBSA-N

物化性质

• 熔点：
  120-122 °C
• 沸点：
  364.1±10.0 °C(Predicted)
• 密度：
  1.017±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF<br/>[FR] STÉROÏDES NEUROACTIFS, LEURS COMPOSITIONS ET UTILISATIONS
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2015180679A1

  公开（公告）日：2015-12-03

  Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I) : and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

  本文提供了式(I)的19-去C3，3-二取代类固醇及其药用可接受的盐；其中R1、R2、R3和R4如本文所定义，A是包含3个或4个氮原子的杂环芳基环系统，如本文所定义。这些化合物被认为对预防和治疗各种与中枢神经系统相关的疾病有用，例如治疗睡眠障碍、情绪障碍、精神分裂症谱系障碍、癫痫性障碍、记忆和/或认知障碍、运动障碍、人格障碍、自闭症谱系障碍、疼痛、创伤性脑损伤、血管疾病、物质滥用障碍和/或戒断综合征，以及耳鸣症的治疗。
• 19-nor neuroactive steroids and methods of use thereof
  申请人：SAGE THERAPEUTICS, INC.

  公开号：US10023606B2

  公开（公告）日：2018-07-17

  Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus.

  本文提供的是符合式（I）的 3,3-二取代 19-去甲甾醇化合物： 及其药物组合物。此类化合物可用于预防和治疗各种中枢神经系统相关疾病，例如治疗睡眠障碍、情绪障碍、精神分裂症谱系障碍、记忆和/或认知障碍、运动障碍、人格障碍、自闭症谱系障碍、疼痛、脑外伤、血管疾病、药物滥用障碍和/或戒断综合征、耳鸣、癫痫状态。
• 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID FOR USE IN THERAPY
  申请人：Sage Therapeutics, Inc.

  公开号：EP3498725B1

  公开（公告）日：2021-06-09
• 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF
  申请人：SAGE THERAPEUTICS, INC.

  公开号：US20170233432A1

  公开（公告）日：2017-08-17

  Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus.
• NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF
  申请人：Botella Gabriel Martinez

  公开号：US20180179247A1

  公开（公告）日：2018-06-28

  Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R 1 , R 2 , R 3 , and R 4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.